Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: June 6th 2024 | Updated: November 2nd 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 20th 2022 | Updated: November 2nd 2024
Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL
Published: October 26th 2021 | Updated: November 2nd 2024
Part 1: Treatment Options and Relevant Data for Patients With DLBCL
Published: February 14th 2022 | Updated: November 2nd 2024
Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL
Published: October 29th 2024 | Updated: November 2nd 2024
FDA Approves Asciminib in Newly Diagnosed Ph+ CML in Chronic Phase